Chemkart India Ltd
Incorporated in 2020, Chemkart India Limited, based in Mumbai, is a B2B nutraceutical ingredient distributor and processor.[1]
- Market Cap ₹ 287 Cr.
- Current Price ₹ 238
- High / Low ₹ 262 / 230
- Stock P/E 11.8
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 61.5 %
- ROE 59.0 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 63.1%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Fast Moving Consumer Goods Fast Moving Consumer Goods Food Products Other Food Products
Part of BSE SME IPO
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 87 | 131 | 132 | 203 | |
| 80 | 120 | 111 | 171 | |
| Operating Profit | 7 | 11 | 21 | 33 |
| OPM % | 8% | 8% | 16% | 16% |
| 0 | 0 | 1 | 2 | |
| Interest | 0 | 1 | 1 | 2 |
| Depreciation | 0 | 0 | 0 | 1 |
| Profit before tax | 7 | 11 | 20 | 33 |
| Tax % | 25% | 27% | 27% | 26% |
| 5 | 8 | 15 | 24 | |
| EPS in Rs | 40.38 | 56.45 | 107.00 | 25.55 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 33% |
| TTM: | 54% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 64% |
| TTM: | 67% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 63% |
| Last Year: | 59% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 10 |
| Reserves | 5 | 13 | 28 | 44 |
| 6 | 11 | 13 | 17 | |
| 12 | 12 | 12 | 16 | |
| Total Liabilities | 25 | 37 | 54 | 86 |
| 1 | 6 | 5 | 9 | |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| 24 | 32 | 48 | 77 | |
| Total Assets | 25 | 37 | 54 | 86 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -6 | 0 | -0 | 4 | |
| -1 | -5 | -0 | -4 | |
| 7 | 5 | 0 | 3 | |
| Net Cash Flow | -0 | 0 | -0 | 3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 80 | 62 | 87 | 82 |
| Inventory Days | 9 | 25 | 27 | 50 |
| Days Payable | 41 | 34 | 33 | 23 |
| Cash Conversion Cycle | 49 | 53 | 81 | 109 |
| Working Capital Days | 28 | 25 | 66 | 75 |
| ROCE % | 58% | 63% | 62% |
Business Segment[1]
a) Trading Business:(97% of H1FY25 revenue)[2]
The company sources a wide range of nutraceutical ingredients—such as amino acids, vitamins, herbal extracts, and proteins—mainly through imports, and supplies them to B2B clients for manufacturing finished supplements.